Objectives: To compare the relative efficacy of the ALK-tyrosine kinase inhibitor (TKI) lorlatinib, investigated in the single-arm Phase I/II trial B7461001 as a second-line or later treatment for patients with advanced ALK-positive NSCLC, to chemotherapy, a key comparator within this indication. Conclusions Lorlatinib consistently demonstrated a significant improvement in the outcomes of both PFS and OS when compared with chemotherapy, although the evidence base is limited. READ ARTICLE
Value in Health DOI:10.1016/j.jval.2020.08.143
Authors: S. Smith, F. Albuquerque de Almeida, M. Inês, L. Iadeluca, M. Cooper
